• Link to Facebook
  • Link to X
  • Link to LinkedIn
  • Link to Youtube
  • Link to Mail
  • For Patients
  • Customer Login
  • Newsletter Sign-up
Profound Medical
  • Home
  • Physicians
    • Customizable Incision-Free Therapies
  • Technology
    • TULSA-PRO®
    • Sonalleve®
  • Company
    • About
    • Leadership Team
    • Board of Directors
    • Careers
  • Investors
    • Profile
    • Governance
    • Presentations
    • TACT Data
    • Webcasts
    • Financial
    • Press Releases
    • Analyst Coverage
    • Subscribe
  • Clinical Publications
    • Clinical Outcomes for Localized Prostate Cancer
    • Demonstrating Feasibility in other Prostate Disease States
    • Review Articles and Commentaries
    • Early Development
  • PRO-Talk Academy
  • Reimbursement
  • Contact
    • Accessibility
  • Menu Menu

What is the difference between TULSA-PRO® and FLA?

Email info@profoundmedical.com for more info today

FLA stands for focal laser ablation. It is also referred to as laser interstitial thermotherapy. FLA is a thermo-ablation technique where high-energy light is emitted from a laser to ablate targeted tissue by means of coagulative necrosis1. During FLA prostate ablation, this energy is delivered to the prostate using a laser fiber that is pushed into the prostate by a transperineal or transrectal approach along a needle guide. The very tip of the laser fiber emits light energy in a spherical area that gets absorbed by the prostate tissue, heating it up to high enough temperatures to ablate the prostate tissue2. This procedure is typically performed under the guidance of real-time MR imaging1.  In one study, all men underwent MRI guided FLA targeting 1 or 2 lesions having tested positive for prostate cancer. With the estimated volume of each lesion being less than 2cm3, the maximum FLA ablation diameter was 15 millimeters (3). Larger zones are ablated by retracing the laser and repeating the ablation, or by inserting the laser in another location. In another study, two different sized laser applicators were used to ablate small and large tumors: the small applicator had a 1cm heat-diffusing tip, and the other had a 1.5cm heat-diffusing tip4. Another study with 24 months of follow-up data published in 2019 with the largest cohort for MRI guided FLA, has similar inclusion criteria regarding lesion size and volume5.

TULSA-PRO stands for Transurethral Ultrasound Ablation of the prostate. During the TULSA Procedure, thermal ultrasound energy is delivered directionally from a device within the urethra, known as the ultrasound applicator. The ultrasound heating extends to a radial depth of 30mm away from each of the ten independent 5mm-long elements, enabling ablation of regions with up to 60mm diameter and 50mm length. The device rotates and delivers the ultrasound heat in a sweeping pattern contacting a large volume of tissue in minimal time. The prostate tissue is therefore ablated from an ‘inside-out’ approach by delivering the directional, thermal ultrasound from the urethra outwards to the edge of the target region of prostate, while actively protecting the urethra and rectum through cooling mechanisms. The TULSA-PRO system combines directional, transurethral thermal ultrasound with real-time MR thermometry, providing closed loop feedback which ensures controlled gentle heating on a wide range of prostate sizes, and predictable outcomes within 1mm of the physician defined region. The TULSA-PRO can ablate angular sectors of the prostate with volume anywhere between 1cc to > 100cc for flexible customization of the target volume based on the patient’s disease and desired outcomes.

Read more about the TULSA-PRO® system

TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration.

If you are interested in learning more about this innovative technology, please email  info@profoundmedical.com

Visit our TULSA Procedure Patient website to learn more about the procedure and patient experiences

References

  1. Ganzer, Roman, et al. “Which technology to select for primary focal treatment of prostate cancer?—European Section of Urotechnology (ESUT) position statement.” Prostate cancer and prostatic diseases2 (2018): 175-186.
  1. Van Luijtelaar, Annemarijke, et al. “Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project.” World journal of urology10 (2019): 2147-2153.
  1. Eggener, Scott E., et al. “Phase II evaluation of magnetic resonance imaging guided focal laser ablation of prostate cancer.” The Journal of urology6 (2016): 1670-1675.
  1. Feller, John F., Bernadette M. Greenwood, and R. Jason Stafford. “Transrectal Laser Focal Therapy of Prostate Cancer.” Imaging and Focal Therapy of Early Prostate Cancer. Springer, Cham, (2017). 325-343.
  1. Walser, Eric, et al. “Focal laser ablation of prostate cancer: results in 120 patients with low-to intermediate-risk disease.” Journal of Vascular and Interventional Radiology3 (2019): 401-409.
Share:
  • Share on Facebook
  • Share on X
  • Share on WhatsApp
  • Share on LinkedIn
  • Share by Mail
Search Search

Recent Posts

  • Profound Medical Annual General and Special Meeting of Shareholders Voting Results
  • Profound Medical Annual General and Special Meeting of Shareholders Voting Results
  • Profound Medical Announces First Quarter 2025 Financial Results
  • Profound Medical Announces First Quarter 2025 Financial Results
  • Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference

Categories

  • Blog Post
  • CEO Update
  • Events
  • Frontpage Article
  • News
  • Newswire
  • Uncategorized
  • Whitepapers

Tags

CEO Message CONALLEVE Corona Corona Virus COVID-19 Erectile Dysfunction Erectile Function EUROPE FLA HIFU meeting PATIENT PROFOUND PROSTATE RELEASE SOFTWARE SONALLEVE TACT TDC tulsa TULSA-PRO TULSAPRO TULSAPROCEDURE tulsa procedure TULSA TREATMENT Webinar

Quick Links

  • Home
  • News
  • Patients
  • Physicians
  • Privacy Policy
  • Accessibility

Careers & Training

  • Careers
  • Customer Login
  • TULSA-PRO Training

Head Office

Profound Medical Corp.,
2400 Skymark Avenue,
Unit #6, Mississauga, ON  L4W 5K5, Canada

T: 647.476.1350 
F:
 647.847.3739
info@profoundmedical.com

 
© Copyright - Profound Medical 2025
  • Home
  • Physicians
  • TULSA PRO
  • Patients
  • Company
  • News
  • Investors
  • Contact
  • Customer Login
  • TULSA-PRO Training
  • Privacy Policy
Link to: TULSA-PRO WEBINAR: December 9th 2020 Link to: TULSA-PRO WEBINAR: December 9th 2020 TULSA-PRO WEBINAR: December 9th 2020 Link to: Interview with Dr. Sharma Link to: Interview with Dr. Sharma Interview with Dr. Sharma
Scroll to top Scroll to top Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

OKLearn More

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, you cannot refuse them without impacting how our site functions. You can block or delete them by changing your browser settings and force blocking all cookies on this website.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visist to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy
Accept settingsHide notification only